
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Cardiovasc. Med.
Sec. Cardio-Oncology
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1559173
This article is part of the Research Topic Case Reports in Cardio-Oncology: 2024 View all 11 articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This manuscript focuses on a case of severe immune-mediated myocarditis caused by sintilimab combined with gemcitabine in a lung cancer patient, along with a comprehensive literature review. It delves into the diagnosis, treatment, and underlying mechanisms of this rare but life-threatening complication within the context of lung cancer immunotherapy. Journals specializing in oncology, particularly those covering immunotherapy in lung cancer and its associated adverse events, would be highly suitable. Additionally, medical journals with a focus on cardiology, especially dealing with immune-related cardiac disorders, would also be a good fit. The manuscript's content aligns well with the scope of such journals as it contributes valuable insights into the intersection of cancer treatment and cardiovascular complications, providing crucial information for clinicians in both specialties to enhance patient management and outcomes.
Keywords: Xiaosha Zhou: Conceptualization, Data curation, Formal analysis, Writing -review & editing. Shanshan Zhang: Data curation, Writing -review & editing. Menglu Sun: Data curation, methodology, Writing -original draft. Xiaoyan Zhang: Conceptualization, investigation
Received: 12 Jan 2025; Accepted: 25 Mar 2025.
Copyright: © 2025 Yang, Sun, Zhou, Han, Zhang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Haixia Yang, Department of Radiotherapy, Xi 'an Chest Hospital Affiliated to Northwest University, Xi'an city, China
Xiaoyan Zhang, Department of Radiotherapy, Xi 'an Chest Hospital Affiliated to Northwest University, Xi'an city, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.